References
- Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995;40(2): 435–56
- Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4): 998–1005
- Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5): 929–38
- Dickson RC, Gaffey MJ, Ishitani MB, et al. The international autoimmune hepatitis score in chronic hepatitis C. J Viral Hepat 1997;4(2): 121–8
- Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23(6): 1369–76
- Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105(6): 1824–32
- Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30(3): 394–401
- Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002;22(4): 339–52
- Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94(7): 1906–13
- Poralla T, Treichel U, Lohr H, et al. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991; 11 (3): 215–22
- Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214): 1510–15
- Muratori L, Cataleta M, Muratori P, et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998;42(5): 721–6
- Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63(5): 820–33
- Uribe M, Go VL, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984;6(4): 331–5
- Summerskill WH, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16(11): 876–83
- Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;57(1): 49–68
- Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 1977:72(5 Pt 1):910–3
- Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBs-Ag negative chronic active hepatitis. Hepatology 1984;4(4): 622–7
- Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80(4): 687–92